Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1

被引：65

作者：

Gupta, A

Cohen, BH

Ruggieri, P

Packer, RJ

Phillips, PC

机构：

[1] Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA

[2] Cleveland Clin Fdn, Brain Tumor Inst, Cleveland, OH 44195 USA

[3] Cleveland Clin Fdn, Ctr Canc, Cleveland, OH 44195 USA

[4] Childrens Natl Med Ctr, Washington, DC 20010 USA

[5] Childrens Hosp, Dept Neurol, Philadelphia, PA 19104 USA

来源：

NEUROLOGY | 2003年 / 60卷 / 01期

关键词：

D O I：

10.1212/01.WNL.0000042321.94839.78

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF). TL was well tolerated in doses up to 200 mg/d. Adverse reactions included transient somnolence in four, evanescent rash in two, and reversible mild peripheral neuropathy in two patients. Four patients showed less than 25% reduction in the tumor size. TL may have a role in the treatment of PNF and should be explored in a larger controlled study, possibly using higher doses of TL.

引用

页码：130 / 132

页数：3

共 11 条

[1] Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2 [J].